erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
biohaven: "rimegepant pivotal phase 3 trial results -- conference call."
.
.turn on desktop notifications for breaking stories about interest?
.